CMMI’s agenda centers on productivity and value-based payment expansion, including outcomes-based reimbursement, Most-Favored ...
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors. This is an ASCO Meeting Abstract from ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果